← Leaderboards
Nicholas J Shaheen
University Of North Carolina Chapel Hill
$48,001,410
Attributed
$79,316,407
Total exposure
14
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $13.3M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$86,119,716 · 15
By mechanism
UL1$30,420,800 · 1
UM1$28,498,535 · 1
U01$12,039,865 · 2
U54$8,300,437 · 3
R01$2,683,423 · 1
T35$1,569,193 · 1
Top collaborators
- Amitabh Chak10 shared
- Sanford D Markowitz10 shared
- John B Buse9 shared
- Sachin Wani9 shared
- William M Grady6 shared
- Valerie L Durkalski5 shared
- Rhonda F Souza5 shared
- Adam Wax5 shared
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Alexander Tropsha$20,747,501
- John B Buse$71,388,050
Others in their field
Top investigators on “Barrett Esophagus”
- Deirdre R. Meldrum · University Of Washington$20,536,912
- Guillermo J. Tearney · Massachusetts General Hospital$18,419,502
- Amitabh Chak · Case Western Reserve University$15,936,499
- Stephen J Meltzer · University Of Maryland Baltimore$14,632,396
- Brian J Reid · Fred Hutchinson Cancer Research Center$12,938,085
- Anil K Rustgi · Columbia University Health Sciences$11,088,470
Research focus
Barrett EsophagusEndoscopyResearch PersonnelMalignant NeoplasmsProgramsEsophageal AdenocarcinomaAreaDesignNorth CarolinaUniversitiesBaseTranslational ResearchIncidenceLeadObesityDetectionGastroesophageal Reflux DiseaseTissuesDiagnosisEnvironmentFundingEsophagusDysplasiaFuture
Grant awards (64)
North Carolina Translational and Clinical Sciences Institute (NC TraCS)$8,559,380
UM1 · FY2025 · TR · contact PI
A Multicenter Randomized Controlled Trial of Surveillance versus. Endoscopic Therapy for Barretts Esophagus with Low-grade Dysplasia: The SURVENT Trial$1,742,655
U01 · FY2025 · DK
Validation of Biomarkers for predicting Barrett's esophagus that will or will not: i) progress towards cancer, or ii) recur after ablation$1,048,823
U01 · FY2025 · CA
North Carolina Translational and Clinical Sciences Institute (NC TraCS)$9,897,097
UM1 · FY2024 · TR · contact PI
A Multicenter Randomized Controlled Trial of Surveillance versus. Endoscopic Therapy for Barretts Esophagus with Low-grade Dysplasia: The SURVENT Trial$2,111,999
U01 · FY2024 · DK
Validation of Biomarkers for predicting Barrett's esophagus that will or will not: i) progress towards cancer, or ii) recur after ablation$996,868
U01 · FY2024 · CA
North Carolina Translational and Clinical Sciences Institute (NC TraCS)$10,042,058
UM1 · FY2023 · TR · contact PI
A Multicenter Randomized Controlled Trial of Surveillance versus. Endoscopic Therapy for Barretts Esophagus with Low-grade Dysplasia: The SURVENT Trial$2,130,120
U01 · FY2023 · DK
Validation of Biomarkers for predicting Barrett's esophagus that will or will not: i) progress towards cancer, or ii) recur after ablation$1,028,348
U01 · FY2023 · CA
North Carolina Translational and Clinical Science Institute (NC TraCS)$9,945,630
UL1 · FY2022 · TR
A Multicenter Randomized Controlled Trial of Surveillance versus. Endoscopic Therapy for Barretts Esophagus with Low-grade Dysplasia: The SURVENT Trial$2,200,000
U01 · FY2022 · DK
Validation of Biomarkers for predicting Barrett's esophagus that will or will not: i) progress towards cancer, or ii) recur after ablation$781,052
U01 · FY2022 · CA
North Carolina Translational and Clinical Science Institute (NC TraCS)$218,324
UL1 · FY2022 · TR
Short Term Research Training$106,212
T35 · FY2022 · DK · contact PI
North Carolina Translational and Clinical Science Institute (NC TraCS)$10,093,886
UL1 · FY2021 · TR
Advanced a/LCI systems for improved clinical utility$553,002
R01 · FY2021 · CA
CAMP FHIR: Lightweight, Open-Source FHIR Conversion Software to Support EHR Data Harmonization and Research$203,479
UL1 · FY2021 · TR
CTSA Diversity Supplement - Vielot - Effectiveness of Recombinant Herpes Zoster Vaccine in Older U.S. Adults$169,963
UL1 · FY2021 · TR
Short Term Research Training$86,662
T35 · FY2021 · DK · contact PI
North Carolina Translational and Clinical Science Institute (NC TraCS)$9,279,679
UL1 · FY2020 · TR
Advanced a/LCI systems for improved clinical utility$564,879
R01 · FY2020 · CA
ICEES+ COVID-19 Open Infrastructure to Democratize and Accelerate Cross-Institutional Clinical Data Sharing and Research$412,692
UL1 · FY2020 · TR
A Multicenter Randomized Controlled Trial of Surveillance versus. Endoscopic Therapy for Barretts Esophagus with Low-grade Dysplasia: The SURVENT Trial$384,138
U34 · FY2020 · DK
Short Term Research Training$144,143
T35 · FY2020 · DK · contact PI
CTSA Administrative Supplement for Quality Assurance/Quality Control Position$97,147
UL1 · FY2020 · TR
Advanced a/LCI systems for improved clinical utility$575,728
R01 · FY2019 · CA
Short Term Research Training$119,609
T35 · FY2019 · DK · contact PI
Advanced a/LCI systems for improved clinical utility$488,713
R01 · FY2018 · CA
Short Term Research Training$131,379
T35 · FY2018 · DK · contact PI
Advanced a/LCI systems for improved clinical utility$501,101
R01 · FY2017 · CA
Non-Endoscopic Surveillance for Barrett's Esophagus Following Ablative Therapy$176,961
K24 · FY2017 · DK · contact PI
Short Term Research Training$150,926
T35 · FY2017 · DK · contact PI
GENETIC DETERMINANTS OF BARRETT'S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA$462,954
U54 · FY2016 · CA
Non-Endoscopic Surveillance for Barrett's Esophagus Following Ablative Therapy$180,183
K24 · FY2016 · DK · contact PI
Short Term Research Training$140,727
T35 · FY2016 · DK · contact PI
GENETIC DETERMINANTS OF BARRETT'S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA$1,446,550
U54 · FY2015 · CA
Non-Endoscopic Surveillance for Barrett's Esophagus Following Ablative Therapy$180,349
K24 · FY2015 · DK · contact PI
Can quercetin increase claudin-4 and improve esophageal barrier function in$143,888
R21 · FY2015 · DK · contact PI
Short Term Research Training$141,857
T35 · FY2015 · DK · contact PI
Building a Better Neosquamous Barrier$62,563
U54 · FY2015 · CA · contact PI
GENETIC DETERMINANTS OF BARRETT'S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA$1,424,703
U54 · FY2014 · CA
Can quercetin increase claudin-4 and improve esophageal barrier function in$257,264
R21 · FY2014 · DK
Non-Endoscopic Surveillance for Barrett's Esophagus Following Ablative Therapy$181,361
K24 · FY2014 · DK · contact PI
Short Term Research Training$165,915
T35 · FY2014 · DK · contact PI
Building a Better Neosquamous Barrier$79,012
U54 · FY2014 · CA · contact PI
GENETIC DETERMINANTS OF BARRETT'S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA$1,268,396
U54 · FY2013 · CA
Non-Endoscopic Surveillance for Barrett's Esophagus Following Ablative Therapy$177,185
K24 · FY2013 · DK · contact PI
Short Term Research Training$155,119
T35 · FY2013 · DK · contact PI
Building a Better Neosquamous Barrier$71,933
U54 · FY2013 · CA · contact PI
GENETIC DETERMINANTS OF BARRETT'S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA$1,174,448
U54 · FY2012 · CA
Racial Disparity in Barrett's Esophagus$395,905
U54 · FY2012 · CA · contact PI
Short Term Research Training$226,644
T35 · FY2012 · DK · contact PI
Building a Better Neosquamous Barrier$67,826
U54 · FY2012 · CA · contact PI
GENETIC DETERMINANTS OF BARRETT'S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA$1,026,258
U54 · FY2011 · CA
Racial Disparity in Barrett's Esophagus$395,586
U54 · FY2011 · CA · contact PI
Racial Disparity in Barrett's Esophagus$424,303
U54 · FY2010 · CA · contact PI
The Perception of Cancer Risk in Patients with Barrett's Esophagus$147,955
R03 · FY2007 · DK · contact PI
Perception of Cancer Risk in Patients with Barrett's$152,094
R03 · FY2006 · DK · contact PI
Epidemiologic Case-control Study of Barrett's Esophagus$125,217
K23 · FY2005 · DK
Epidemiologic Case-control Study of Barrett's Esophagus$125,217
K23 · FY2004 · DK
Epidemiologic Case-control Study of Barrett's Esophagus$125,217
K23 · FY2003 · DK
Epidemiologic Case-control Study of Barrett's Esophagus$125,217
K23 · FY2002 · DK
Epidemiologic Case-control Study of Barrett's Esophagus$125,217
K23 · FY2001 · DK
GENE PREVALENCE OF THE C282Y MUTATION IN DIABETIC PTS$0
M01 · FY2000 · RR